Penn State Health Children’s Hospital received a $400,000 grant from Hyundai Hope On Wheels on Sept. 26, 2025, to support pediatric cancer research led by Dr. Giselle Sholler, division chief of Pediatric Hematology-Oncology, according to Penn State Health News. The funding aims to advance clinical trials and expand treatment options for children battling rare and difficult-to-treat cancers.
Grant Presentation and Community Impact
The grant presentation took place at Penn State Health Children’s Hospital during an event that brought together hospital leaders, Hyundai representatives, patients, and families. According to Penn State Health News, a local family affected by pediatric cancer shared their personal story during the program to highlight the real-life impact of ongoing research advancements.
Following the remarks and check presentation, young patients participated in the signature Handprint Ceremony. Children dipped their hands in paint and pressed colorful handprints onto a white Hyundai vehicle, a nationwide tradition symbolizing hope, resilience, and unity in the fight against childhood cancer. Eleven-year-old Linaya Shadel was among the participants who placed a painted hand on a car window during the event.
Advancing Pediatric Oncology Research
Dr. Giselle Sholler, a nationally recognized leader in pediatric oncology research, directs innovative clinical trials and collaborates with institutions across the country to develop new therapies. According to Penn State Health News, the $400,000 2025 Scholar Hope Grant will help accelerate her team’s efforts to improve survival rates and expand treatment options for young patients.
The award is part of Hyundai Hope On Wheels’ broader $27 million national commitment in 2025. This latest round of funding brings the nonprofit organization’s lifetime investment in pediatric cancer research to $277 million since its founding in 1998.
National Partnership and Legacy
Hyundai Hope On Wheels has partnered with more than 175 research institutions nationwide. By providing critical financial support, the organization seeks to advance innovative treatments and ultimately find a cure for childhood cancers.
Related reading
- Face Lift Surgery vs. Ulthera: Which Lifting Method is Right for You?
- Endometriosis: Patients and Doctors Question Standard Treatments
- Oregon State Capitol in Salem (news-usa.today)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)